Highlights Prostatype Genomics AB

Equities

PROGEN

SE0014684569

Delayed Nasdaq Stockholm Other stock markets 05:56:59 24/06/2024 pm IST			5-day change	1st Jan Change
0.027 ^SEK	+10.20%		+20.00%	-71.58%

23/05	Prostatype Genomics AB Elects Johan Waldhe as New Member of the Board	CI
18/04	Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala	18/04	CI
Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®	17/04	CI
Prostatype Genomics Wraps Up Prostate Cancer Genetic Test Study with Positive Results	16/04	MT
Prostatype Genomics Announces Strong Positive Final Results from Multicentre Study with Prostatype®? in Spain	16/04	CI
Prostatype Genomics AB Announces Strong Positive Final Results from Multicentre Study with Prostatype in Spain	16/04	CI
Prostatype Genomics Enters into Collaboration with Professor E. David Crawford University of California San Diego, in Preparation for the Commercial Launch of Prostatype in the United States	02/04	CI
Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Prostatype Genomics AB Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®	22/12	CI
Prostatype Genomics Secures Prostate Cancer Test Order From Swiss Institution; Shares Surge	01/11	MT
Prostatype Genomics AB Receives the First Order of Prostatype in Switzerland from One of the Country's Major University Hospitals	01/11	CI
Prostatype Genomics AB Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype Genomics	30/23/30	CI
Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)	25/23/25	CI
Prostatype Genomics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI
Prostatype Genomics AB Provides Revenue Guidance for the Third Quarter of 2023	17/23/17	CI
Prostatype Genomics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	31/23/31	CI
Prostatype Genomics Enters Collaboration with Eurofins Megalab	29/23/29	CI
Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2022	16/23/16	CI
Prostatype Genomics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	16/23/16	CI
Prostatype Genomics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Prostatype Genomics AB Provides Sales Guidance for the Year 2022	07/22/07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Prostatype Genomics AB

Equities

PROGEN

SE0014684569

Highlights

Filters